🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Caroline Robert

Université Paris-Sud

ORCID: 0000-0002-9493-0238

Also affiliated with Inserm, Université Paris-Saclay, Institut Gustave Roussy

MedicineBiochemistry, Genetics and Molecular BiologyImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

3in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 3 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Top data-sharing exemplar

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Data from Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases

(2023)10.1158/1078-0432.c.6533110
Top 100%
0DataRank
Top 100%0 citations

Hussein A. Tawbi, Johnathan A. Engh, Nduka Amankulor, Brindha Shivalingam, Hiya Banerjee +13 more

Papers

Driven by 15 papers — median percentile 0. Top paper: “Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial”.

Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

The Lancet(2015)10.1016/s0140-6736(15)60898-4
N/A
13.9DataRank · unranked
1394 citations

Daniil Stroyakovskiy, Helen Gogas, Evgeny Levchenko, Filippo de Braud, James Larkin +29 more

Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation study

The Lancet Oncology(2021)10.1016/s1470-2045(20)30726-9
N/A
4.9DataRank · unranked
94 citations

Jennifer Wiggins, Broderick C. Corless, Georgina V. Long, Keith T. Flaherty, Dirk Schadendorf +12 more

Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma

European Journal of Cancer(2020)10.1016/j.ejca.2020.11.010
N/A
3.9DataRank · unranked
100 citations

Wen-Jen Hwu, Omid Hamid, Antoni Ribas, Jeffrey S. Weber, Adil Daud +18 more

PD-1 blockade induces responses by inhibiting adaptive immune resistance

Nature(2014)10.1038/nature13954
N/A
1.3DataRank · unranked
6579 citations

Christina L. Harview, Jennifer H. Yearley, I. Peter Shintaku, Emma J. M. Taylor, Lidia Robert +28 more

PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma

Nature Communications(2020)10.1038/s41467-020-19810-w
N/A
0.675DataRank · unranked
89 citations

Alain P. Algazi, Paolo A. Ascierto, Marcus O. Butler, Sunandana Chandra, Michael S. Gordon +10 more

Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-2581
N/A
0.636DataRank · unranked
17 citations

Hussein A. Tawbi, Johnathan A. Engh, Nduka Amankulor, Brindha Shivalingam, Hiya Banerjee +13 more

Dermatologic Side Effects of Systemic Targeted Anticancer Therapy

Side Effects of Medical Cancer Therapy(2018)10.1007/978-3-319-70253-7_11
N/A
0.230DataRank · unranked
1 citations

Christina Mateus, Alexander M. M. Eggermont, Caroline Robert

Dermatologic Side Effects of Systemic Anticancer Therapy

Side Effects of Medical Cancer Therapy(2013)10.1007/978-0-85729-787-7_10
N/A
0.125DataRank · unranked
1 citations

Christina Mateus, Alexander M. M. Eggermont, Caroline Robert

International real-world study of combination immunotherapy sequences in metastatic melanoma

Journal for ImmunoTherapy of Cancer(2025)10.1136/jitc-2025-012225
N/A
0.104DataRank · unranked
1 citations

Sarah E. Lochrin, James W. Smithy, Michael A. Postow, Caroline Gaudy‐Marqueste, Nausicaa Malissen +28 more

Loss of Ambra1 promotes melanoma growth and invasion

Nature Communications(2021)10.1038/s41467-021-22772-2
N/A
0DataRank · unranked
66 citations

Valérie Bodemeyer, Francesca M. Bosisio, Giuseppina Claps, Marco Carretta, Salvatore Rizza +18 more

Long-term outcomes among patients who respond within the first year to nivolumab plus ipilimumab or nivolumab monotherapy: A pooled analysis in 935 patients

European Journal of Cancer(2024)10.1016/j.ejca.2024.115119
N/A
0DataRank · unranked
14 citations

G.V. Long, John O. Larkin, Jedd D. Wolchok, J.C. Hassel, D. Schadendorf +16 more

Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition

Journal of Hematology & Oncology(2025)10.1186/s13045-024-01634-6
N/A
0DataRank · unranked
131 citations

Hannah Lau, Lukas M. Carter, E. Hui Clarissa Lee, Hiu Yan Lam, Elena Okina +34 more

Cancer drug-tolerant persister cells: from biological questions to clinical opportunities

Nature reviews. Cancer(2024)10.1038/s41568-024-00737-z
N/A
0DataRank · unranked
156 citations

Mengnuo Chen, Elisa Mariella, Haoning Peng, Sumaiyah K. Rehman, Elena Sancho +17 more

Data from Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases

(2023)10.1158/1078-0432.c.6533110
Top 100%
0DataRank
Top 100%0 citations

Hussein A. Tawbi, Johnathan A. Engh, Nduka Amankulor, Brindha Shivalingam, Hiya Banerjee +13 more

Data from Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases

(2023)10.1158/1078-0432.c.6533110.v1
Top 100%
0DataRank
Top 100%0 citations

Hussein A. Tawbi, Johnathan A. Engh, Nduka Amankulor, Brindha Shivalingam, Hiya Banerjee +13 more